New pharmacologic approaches to the treatment of diabetes.
D050260:Carbohydrate Metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005934:Glucagon / Q000031:analogs & derivatives / Q000627:therapeutic use; D005943:Gluconeogenesis / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D007333:Insulin Resistance; D000078790:Insulin Secretion; D011759:Pyrrolidines / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D011759:Pyrrolidines; D013453:Sulfonylurea Compounds; C021239:pirogliride; D013004:Somatostatin; D005934:Glucagon